Non-invasive Diagnosis of Invasive Pulmonary Aspergillosis by Use of Biomarkers in Exhaled Breath Condensate (NIPA)
-
- STATUS
- Recruiting
-
- End date
- Dec 31, 2026
-
- participants needed
- 57
-
- sponsor
- Inger Lise Gade
Summary
In this study, a new, non-invasive method for diagnosis of pulmonary aspergillosis (PA) will be tested in a clinical pilot project.
Description
- Background
The search for biomarkers to enhance and improve diagnosis of PA is ongoing, mainly focused on markers detected in the blood and bronchoalveolar lavage (BAL) fluids. In this study, the investigators will investigate whether exhaled breath condensate is a useful source for diagnosis of PA either by existing methods (i.e. polymerase chain reaction (PCR) detection of Aspergillus DNA) or by analysis of the proteome. However, extraction of Aspergillus DNA has never been done in the EBC before. In this pilot study the investigators will investigate whether it is possible to purify DNA from pneumocystis from EBC of patients with proven pneumocystis pneumonia both because the diagnostic test for pneumocystis pneumonia is more sensitive and specific and also due to the fact that pneumocystis pneumonia is more common than PA. The investigators will spare the EBC samples from patients PA for the protein analysis in this study.
No previous studies have investigated the potential of EBC protein analysis as a diagnostic tool in PA infections. In this pilot study, the investigators will test whether Aspergillus proteins are present in the EBC from patients with proven/probable/possible PA.
- Methods
The study will compare the protein profiles of exhaled breath condensate (EBC) collected from patients with proven, probable or possible pulmonary aspergillus (PA) infection and patients with suspected PA infection where routine diagnostic workup ruled out PA, and negative controls, i.e. patients who undergo diagnostic workup for benign/indolent conditions and without suspected PA, with same age (within a range of 10 years) and gender from the outpatient clinic at department of hematology, department of infectious diseases, department of respiratory diseases and department of cardiothoracic surgery at Aalborg University Hospital. The main-outcome, i.e. means of the relative amounts of specific proteins in the EBC samples, will be compared by unpaired t-tests after assessment of normality and standard deviations within the two groups in the following comparisons: proven/probable/possible PA vs. patients where PA was ruled out and proven/probable/possible PA vs. negative controls. In case three groups are compared, the one-way analysis of variance will be applied, but this is not within the main scope of our study.
In a sub-study, the investigators will collect EBC from patients with suspected Pneumocystis jirovecii pneumonia and healthy controls, i.e. patients who undergo diagnostic workup for benign/indolent conditions and without suspected pneumocystis pneumonia. Diagnostic tests for pneumocystis pneumonia are highly specific and sensitive. The investigators will test whether pneumocystis DNA is detectable in the EBC from these patients and learn how DNA should be extracted from the EBC samples. DNA extraction and analysis will be done locally. The investigators will use the experiences and results from this sub-study in the design of further studies of detection of Aspergillus in the EBC after this pilot study, if relevant. The investigators will include four patients with confirmed pneumocystis pneumonia and four healthy controls. Oral washes pneumocystis tests will be collected immediately before the EBC is collected for both cases and healthy controls. If the diagnosis of pneumocystis pneumonia is not confirmed in a patient with suspected pneumocystis pneumonia, the patient will be included as negative control.
Blood samples (i.e. excess plasma/serum from routine blood samples drawn as a part of routine diagnostic work-up) from the study participants (both PA-patients, healthy controls, and pneumocystis pneumonia patients) will be stored for standardization and verification and supplementing analysis of possible findings in the EBC. Plasma is the part of a blood sample that is left after centrifugation when an anticoagulant agent is added upon drawing of the blood sample. Hence, for some of the samples (citrate, ethylenediaminetetraacetic acid (EDTA), heparin coated tubes), the investigators will store plasma (i.e. cell-free part of the blood with coagulation factors) and for the blood sample that was allowed to coagulate in the tube, the stored material will be serum (i.e. cell-free part of the blood without coagulation factors). In order to qualify the most suitable markers and substrates for standardization, the analysis of the EBC samples must be completed before the blood samples can be analyzed. Only biochemical, no genetic analysis will be conducted. For the healthy PA controls, the investigators will ask for an extra blood sample for detection of aspergillus galactomannan. For the healthy pneumocystis pneumonia controls, the investigators will ask for a pneumocystis oral wash for test of pneumocystis.
Details
| Condition | Aspergillosis Pneumonia, Pneumocystis Pneumonia |
|---|---|
| Treatment | Aspergillus specific proteins in exhaled breath condensate (EBC), Pneumocystis jirovecii DNA in exhaled breath condensate (EBC) |
| Clinical Study Identifier | NCT04358419 |
| Sponsor | Inger Lise Gade |
| Last Modified on | 22 March 2022 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer